Author | Jonathon B. Cohen, MD, MS


The Role of the Comprehensive Geriatric Assessment in the Evaluation of the Older Cancer Patient

November 14, 2019

ByCarmelo Blanquicett, MD, PhD, FACP|Theodore Johnson, II, MD, MPH|Christopher Flowers, MD, MS|Jonathon B. Cohen, MD, MS

Geriatric assessments have now been recommended as part of the standard evaluation of an older adult considering cancer therapy.

How to Decide Which DLBCL Patients Should Receive CNS Prophylaxis

June 15, 2018

ByKevin H. Hall, PharmD, BCOP|Elyse Hall Panjic, PharmD, BCOP|Kelly Valla, PharmD, BCOP|Christopher R. Flowers, MD, MS|Jonathon B. Cohen, MD, MS

Here we review current prognostic models, risk factors, and prophylaxis methods to provide a practical approach to preventing CNS relapse in patients with DLBCL.

PI3K Inhibitors: Understanding Toxicity Mechanisms and Management

November 15, 2017

ByI. Brian Greenwell, MD|Andrew Ip, MD|Jonathon B. Cohen, MD, MS

Here, we briefly describe the clinical efficacy of PI3K inhibitors, then discuss the mechanisms and management of the more common unusual toxicities seen with these agents.

A Plethora of Novel Therapies-Which One to Choose?

July 15, 2015

ByJonathon B. Cohen, MD, MS|Christopher R. Flowers, MD, MS

While the headliners for the 2015 ASCO Annual Meeting featured mainly immunologic approaches to cancer treatment, with agents such as nivolumab and ipilimumab, the new data in hematologic malignancies highlighted a large number of novel therapies, each of which appears promising.